Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TPH1 | P17752 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15230828 | 0.88 | GAA (0.38) | GAAPPARGCCR1MEN1KMT2A | |
| SCHEMBL1765165 | 0.88 | CCR1 (0.44) | GAAPPARGCCR1MEN1KMT2A | |
| SCHEMBL15230212 | 0.86 | CCR1 (0.41) | GAACCR1MEN1KMT2ATRPV1 | |
| SCHEMBL15231257 | 0.85 | PPARG (0.38) | GAAPPARGCYP3A4MEN1KMT2A | |
| SCHEMBL15230947 | 0.84 | CCR1 (0.40) | GAAPPARGCCR1MEN1KMT2A | |
| SCHEMBL15231742 | 0.83 | CCR1 (0.43) | GAACCR1MEN1KMT2ATRPV1 | |
| SCHEMBL1765093 | 0.83 | CCR1 (0.42) | GAAPPARGCCR1TPH1ALDH1A1 | |
| SCHEMBL15230430 | 0.82 | CCR1 (0.40) | GAAPPARGCCR1MEN1KMT2A | |
| SCHEMBL15230786 | 0.79 | FAAH (0.42) | GAA | |
| SCHEMBL15231151 | 0.78 | CCR1 (0.38) | GAAPPARGCCR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160007606-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-01-14 | — | — | US | disclosed |
| EP-2820012-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Syngenta Participations AG (CH) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013127784-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160007606-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | PRF1, CASP1, MPO | GAA 2269/4885PPARG 355/4885CCR1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.